Anavex 2-73 Earns U.S. Patent for Neurodevelopmental Disorders, Including Rett Syndrome
The United States Patent and Trademark Office (USPTO) granted a patent to Anavex Life Sciences covering Anavex 2-73 (blarcamesine) as a potential therapy for neurodevelopmental disorders, including Rett syndrome. The patent (No. 10,507,196) is valid until at least 2037 and also covers methods of treatment based on…